People | July 27, 2025
Granules India CEO K V Sitaram Rao resigns
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Subscribe To Our Newsletter & Stay Updated
